References of "Van Riet, Ivan"
     in
Bookmark and Share    
See detailCord blood for allogeneic use: Clinical and scientific aspects?
BAUDOUX, Etienne ULg; BEGUIN, Yves ULg; Benoit, Yves et al

Report (2012)

In this science-policy advisory report, the Superior Health Council issues advice on cord blood as an allogeneic source of stem cells for human clinical use

Detailed reference viewed: 10 (2 ULg)
See detailAutologous cord blood use: Clinical and scientific aspects
Angenon, Elyane; BAUDOUX, Etienne ULg; BEGUIN, Yves ULg et al

Report (2011)

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailNeighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells
CAERS, Jo ULg; Deleu, Sara; Belaid, Zakia et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2007), 21(7), 1580-4

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailDe bijdrage van muismodellen bij studies naar multipel myeloom
Vanderkerken, Karin; Van Valckenborgh, Els; Menu, Eline et al

in Nederlands Tijdschrift voor Hematologie (2007), 4(4), 193-143

Detailed reference viewed: 21 (0 ULg)
Full Text
Peer Reviewed
See detailEndothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within the murine 5T33MM model and myeloma patients.
De Bruyne, Elke; Andersen, T. L.; De Raeve, Hendrik et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2006), 20(10), 1870-9

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailThe involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM model
Caers, Jo ULg; Günthert, Ursula; De Raeve, Hendrik et al

in British Journal of Haematology (2006), 132((4)), 469-77

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailOf mice and men: disease models of multiple myeloma
Caers, Jo ULg; Asosingh, Kewal; Van Camp, Ben et al

in Drugs Discovery Today: disease models (2005), 1(4), 373-380

Detailed reference viewed: 18 (1 ULg)
Peer Reviewed
See detailExpression of osteopontin and its receptor the alphavbeta3 integrin in the 5TMM myeloma model
CAERS, Jo ULg; De Raeve, Hendrik; Asosingh, Kewal et al

Poster (2004, September 17)

NA

Detailed reference viewed: 19 (0 ULg)
Full Text
Peer Reviewed
See detailMultifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model
Van Valckenborgh, Els; Croucher, Peter I.; De Raeve, Hendrik et al

in American Journal of Pathology (2004), 165(3), 869-878

Matrix metalloproteinases (MMPs) are known to play a role in cell growth, invasion, angiogenesis, metastasis, and bone degradation, all important events in the pathogenesis of cancer. Multiple myeloma is ... [more ▼]

Matrix metalloproteinases (MMPs) are known to play a role in cell growth, invasion, angiogenesis, metastasis, and bone degradation, all important events in the pathogenesis of cancer. Multiple myeloma is a B-cell cancer characterized by the proliferation of malignant plasma cells in the bone marrow, increased angiogenesis, and the development of osteolytic bone disease. The role of MMPs in the development of multiple myeloma is poorly understood. Using SC-964, a potent inhibitor of several MMPs (MMP-2, -3, -8, -9, and -13), we investigated the role of MMPs in the 5T2MM murine model. Reverse transcriptase-polymerase chain reaction demonstrated the presence of mRNA for MMP-2, -8, -9, and -13 in 5T2MM-diseased bone marrow. Mice bearing 5T2MM cells were given access to food containing SC-964. The concentration of SC-964 measured in the plasma of mice after 11 days of treatment was able to inhibit MMP-9 activity in gelatin zymography. Treatment of 5T2MM-bearing mice resulted in a significant reduction in tumor burden, a significant decrease in angiogenesis, and partially protective effect against the development of osteolytic bone disease. The direct role of MMPs in these different processes was confirmed by in vitro experiments. All these results support the multifunctional role of MMPs in the development of multiple myeloma. [less ▲]

Detailed reference viewed: 23 (1 ULg)
Full Text
Peer Reviewed
See detailPrognostic Value of Bone Sialoprotein Expression in Clinically Localized Human Prostate Cancer
Waltregny, David ULg; Bellahcene, Akeila ULg; Van Riet, Ivan et al

in Journal of the National Cancer Institute (1998), 90(13), 1000-8

BACKGROUND: Bone sialoprotein (BSP), a bone matrix protein, was recently found to be expressed ectopically in breast cancer and to have a statistically significant association with poor prognosis and the ... [more ▼]

BACKGROUND: Bone sialoprotein (BSP), a bone matrix protein, was recently found to be expressed ectopically in breast cancer and to have a statistically significant association with poor prognosis and the development of bone metastases in that disease. These data prompted us to investigate whether BSP might also be expressed in human prostate cancer, which often metastasizes to bone, and be predictive for progression risk. METHODS: Tissue sections from 180 patients who had undergone a radical prostatectomy for localized prostate cancer were analyzed immunohistochemically for BSP expression. Biochemical progression was defined as an increasing serum prostate-specific antigen level of 0.5 ng/mL or more. Statistical analysis was used to assess associations between pathologic findings and level of BSP expression, and a Cox proportional hazards model was used to determine which clinical and histologic parameters, including stage, Gleason score, and BSP expression (immunostaining intensity and extent), were independently associated with biochemical progression. All P values were two-sided. RESULTS: Most of the prostate cancer lesions examined (78.9%) expressed detectable levels of BSP, compared with no or low expression in the adjacent normal glandular tissue. A statistically significant association was found between BSP expression and biochemical progression in both univariate and multivariate analyses. After a follow-up interval of 3 years, the biochemical relapse rate was 36.7% (95% confidence interval [CI] = 23.4%-47.7%) in patients whose tumors expressed high levels of BSP compared with 12.1% (95% CI = 2.3%-20.8%) in patients whose tumors expressed no or a low detectable level of the protein (logrank test, P = .0014). BSP expression status could identify those patients at higher risk of biochemical progression (logrank test, P<.05) among patients with moderately differentiated tumors or with pathologically confined tumors. CONCLUSIONS: To our knowledge, this study is the first to demonstrate BSP expression in human prostate cancer and to highlight the protein's statistically significant prognostic value in patients with clinically confined prostate adenocarcinomas. [less ▲]

Detailed reference viewed: 10 (2 ULg)
Peer Reviewed
See detailExpression of bone sialoprotein in human prostate is associated with progression
Waltregny, David ULg; Bellahcene, Akeila ULg; Van Riet, Ivan et al

Conference (1998, January 23)

Detailed reference viewed: 7 (2 ULg)
Peer Reviewed
See detailExpression of bone sialoprotein in human prostate cancer is associated with progression
Waltregny, David ULg; Bellahcene, Akeila ULg; Van Riet, Ivan et al

in Acta Clinica Belgica (1998, January), 53(3), 221-240

Detailed reference viewed: 14 (6 ULg)
Peer Reviewed
See detailExpression of bone sialoprotein in human prostate cancer is associated with progression
Waltregny, David ULg; Bellahcene, Akeila ULg; Van Riet, Ivan et al

in Proceedings of the American Association for Cancer Research (1998), 39

Detailed reference viewed: 15 (6 ULg)